GLP-1S
Shop GLP-1SAlso called: GLP-1s, GLP-1 S, GLP1s
GLP-1S is a research peptide sold by online peptide stores. It is not a medicine you can buy at a drugstore. It is meant for lab study only, not for people to take. Small research companies sell it in little bottles called vials.
GLP-1S is related to a natural body signal called GLP-1. This signal helps control blood sugar and hunger after you eat. Many people look for these kinds of compounds because of news about weight-loss drugs that work on the same body signal. There is very little solid research on GLP-1S itself.
It is not approved by the FDA for any use in people. Scientists do not know if it is safe or if it works. Vials bought online may not contain what the label says. Anyone thinking about using it should talk to a doctor first and know the serious risks.
Benefits
What GLP-1S Helps With
The benefits people report — backed by research.
Weight management (2)
Cancer / tumor (1)
More reported benefits (1)
Free: The Peptide Stack Cheat-Sheet
You just read the research on GLP-1S. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Get GLP-1S
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
News
Latest on GLP-1S
Dated, sourced reporting that mentions GLP-1S.
Patients with bipolar disorder benefit from GLP-1s
A Swedish national cohort study of 14,694 people with bipolar disorder found that semaglutide use was associated with a lower risk of psychiatric hospitalization, with no concerning safety signals such as suicidality. Published in Acta Psychiatrica Scandinavica, the study analyzed 2009-2024 registry data from patients using diabetes medications. This is the first study to evaluate GLP-1 receptor agonists in people with bipolar disorder, despite frequent co-occurrence of diabetes, obesity, and bipolar disorder.
Wegovy, Zepbound: Guideline advises GLP-1s as first-line obesity drugs
The American College of Physicians has issued a new clinical guideline naming semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) as preferred first-line drug treatments for adults with obesity, used alongside lifestyle changes. The recommendations were published in Annals of Internal Medicine and ranked other options like phentermine-topiramate, liraglutide, and naltrexone-bupropion below these GLP-1-based therapies. The guideline emphasizes individualized decisions weighing benefits, harms, cost, and patient preferences, and is designated a 'living guideline' to be updated as evidence evolves.
Off-brand GLP-1s still widely available despite shortage resolutions
Despite FDA resolution of GLP-1 drug shortages, compounded (non-FDA-approved) versions of semaglutide and tirzepatide remain widely sold through clinics and medical spas. Data presented at the Obesity Medicine Association annual meeting show some suppliers have inconsistent licensure or FDA disciplinary action. Researchers highlight ongoing safety and quality concerns with compounded GLP-1s.
Patients struggle as compounded GLP-1 access rapidly shrinks
Compounded copies of GLP-1 drugs like semaglutide and tirzepatide are being phased out now that regulators no longer consider the branded drugs in shortage. Hundreds of thousands of patients who relied on cheaper compounded versions at around $200 per month must find alternatives, but even discounted brand prices of $350-$700 monthly remain unaffordable for many. Telehealth companies and compounding pharmacies are pursuing risky strategies like changing prescriptions or encouraging stockpiling. Experts describe the situation as a 'lose-lose' for patients.
FDA Roundup: December 17, 2024
The FDA sent warning letters to five companies for selling unapproved GLP-1 peptide products, including semaglutide, tirzepatide, and retatrutide, in interstate commerce. One company, Veronvy, was cited for misbranded oral GLP-1 products falsely claiming FDA approval. The letters target peptide vendors Xcel Peptides, Swisschems, Summit Research, and Prime Peptides. This is part of ongoing FDA enforcement against unapproved GLP-1 sales amid high demand for these drugs.
Wondering how GLP-1S pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →